GlassScriptPhysician profile
Stacy Rose Frederick
NPI 1104250893
$2,258.68
in general payments reported to CMS, 2019-2025
21 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $769 · 2022: $611 · 2023: $464 · 2024: $183 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,183.48 | 2021-2025 | Relistor |
| Tersera Therapeutics LLC | $182.49 | 2021-2025 | Prialt |
| Abbvie INC. | $161.99 | 2021-2025 | |
| Amgen INC. | $119.78 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $112.94 | 2021-2024 | Ztlido |
| Arbor Pharmaceuticals, INC. | $83.47 | 2021-2022 | |
| Eisai INC. | $45.59 | 2021 | |
| Redhill Biopharma INC. | $44.44 | 2021 | |
| Medtronic, INC. | $42.13 | 2025 | Synchromedii |
| Novartis Pharmaceuticals Corporation | $41.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.37 | 2022 | |
| Collegium Pharmaceutical, INC. | $27.51 | 2021 | |
| Nevro Corp. | $25.78 | 2023 | Senza |
| Genentech USA, INC. | $22.92 | 2023 | Polivy, Columvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.67 | 2021 | |
| Grt US Holding, INC. | $21.49 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.91 | 2023 | Quviviq |
| Abbott Laboratories | $14.12 | 2022 | |
| Lilly USA, LLC | $12.94 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.